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The potential benefits of stimulating a patient’s immune
system to fight cancer are profound. Historically, immu-
notherapy has been a successful treatment approach for
some cancer patients, and recent advances in immu-
notherapy highlight that the immune system can gener-
ate durable tumor responses and cures. However, a
concern regarding immunotherapy in cancer patients is
the possibility that the immune response will be compro-
mised by the underlying cancer and/or previous antican-
cer therapies. A promising approach in immunotherapy
is targeting pathogen-associated molecular pattern recep-
tors, such as the Toll-like receptors (TLRs), to activate
the innate immune system and enhance development of
tumor-directed adaptive immune responses. To assess
whether cancer patients exhibit immune insufficiency in
response to the potent and selective TLR8 agonist moto-
limod, we compared the pharmacokinetic and pharmaco-
dynamic (PK/PD) relationship defined in a Phase 1 study
of motolimod in cancer patients to the response in
healthy volunteers.
Stimulation of healthy volunteer human PBMC by
motolimod using the TruCulture® system (Myriad-RBM)
defined the breadth and magnitude of immune mediators
induced by TLR8 activation in vitro. In a Phase 1 dose-
escalation study in patients with advanced solid tumors,
many of these defined mediators of TLR8 activation were
increased in the plasma of cancer patients treated with
motolimod. Notably, multiple biomarkers of immune
activation, including G-CSF, MCP-1, and MIP1-b
increased in a dose-dependent manner and correlated
with increasing plasma levels of motolimod. A second
Phase 1 study of motolimod in healthy volunteers pro-
vided an opportunity to compare and contrast the
immune response generated by treatment with motoli-
mod in healthy volunteers to that observed in cancer
patients.
At comparable dose levels, the PK profile and overall
exposure (AUC) to motolimod were similar for cancer
patients and healthy volunteers. Motolimod induced the
same repertoire of circulating cytokines and chemokines,
indicative of TLR8 activation, in both populations. The
magnitude of the mediator response in cancer patients
was highly comparable to the response in healthy volun-
teers that received a similar dose.
In summary, advanced cancer and prior treatment with
cytotoxic agents did not appear to blunt the response to
motolimod based on the PK/PD relationship using pre-
dictive biomarkers. This comparison demonstrates that
the immune system of cancer patients with advanced dis-
ease remains highly responsive to TLR8 activation by
motolimod.
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